← Leaderboards
Louis Daniel Scampavia
Medical College Of Wisconsin
$25,788,290
Attributed
$47,815,102
Total exposure
31
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.7M · FY2013–25$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$47,815,102 · 31
By mechanism
R01$33,480,760 · 19
U19$7,237,749 · 1
R33$3,805,783 · 3
S10$2,014,533 · 4
R21$761,507 · 2
R61$414,771 · 1
Top collaborators
- Gavin R Rumbaugh15 shared
- Timothy Patrick Spicer14 shared
- Courtney A Miller9 shared
- Benjamin F Cravatt8 shared
- Theodore M Kamenecka8 shared
- Laura A Solt8 shared
- Jarrod B French5 shared
- Nicholas A Carpino4 shared
Most similar at Medical College Of Wisconsin
Same institution · by research overlap
- Jonathan S Marchant$9,493,806
- Earnestine Willis$4,929,457
Others in their field
Top investigators on “High Throughput Screening”
- Richard A Gibbs · Baylor College Of Medicine$250,166,309
- Leonard Freedman · Leidos Biomedical Research, Inc.$249,633,249
- David Heimbrook · Leidos Biomedical Research, Inc.$181,270,700
- Peter B. Gilbert · Fred Hutchinson Cancer Center$146,111,713
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
Research focus
High Throughput ScreeningLibrariesScreeningDrug DiscoveryBaseLeadIn VivoPharmaceutical PreparationsMiniaturizeCellsSmall MoleculePharmaceutical ChemistryValidationSeriesProteinsResponseMouse ModelIn VitroInhibitor/AntagonistPropertyMolecularStructureStructure-Activity RelationshipCytotoxicity
Grant awards (87)
Identifying phosphoribosylformylglycinamidine synthase inhibitors as a new class of purine antimetabolites$549,474
R01 · FY2025 · CA
Identification of novel anthelmintics through a target-based screen of a parasite ion channel$736,086
R01 · FY2024 · AI
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$475,793
R33 · FY2024 · NS
BioRaptr Replacement Dispensers to Support High Throughput Screening$338,686
S10 · FY2024 · OD · contact PI
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$774,212
R01 · FY2023 · MH
Identification of novel anthelmintics through a target-based screen of a parasite ion channel$697,038
R01 · FY2023 · AI
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$497,954
R33 · FY2023 · NS
Core B: Antiviral Drug Discovery and Development$7,237,749
U19 · FY2022 · AI · contact PI
Identification of novel anthelmintics through a target-based screen of a parasite ion channel$612,768
R01 · FY2022 · AI
Optimizing the immune response by targeting the Sts enzymes$563,489
R01 · FY2022 · AI
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$547,173
R01 · FY2022 · MH
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$295,695
R01 · FY2022 · MH
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$229,400
R61 · FY2022 · NS
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$185,371
R61 · FY2022 · NS
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$652,164
R01 · FY2021 · MH
Optimizing the immune response by targeting the Sts enzymes$604,227
R01 · FY2021 · AI
Tandem Multi-modal Plate Readers for a High Throughput Screening platform$516,393
S10 · FY2021 · OD · contact PI
CHEMOPROTEOMIC METHODS FOR SERINE HYDROLASE INHIBITOR DEVELOPMENT$486,911
R01 · FY2021 · DA
Identification of REV-ERB inverse agonists for cancer immunotherapy$392,550
R01 · FY2021 · CA
Identification of novel anthelmintics through a target-based screen of a parasite ion channel$373,743
R01 · FY2021 · AI
Identification of REV-ERB inverse agonists for cancer immunotherapy$289,604
R01 · FY2021 · CA
Tandem Multi-modal Plate Readers for a High Throughput Screening platform$83,607
S10 · FY2021 · OD · contact PI
Parallel Multimodal High-throughput screening to identify activators of the orexin receptors$731,424
R01 · FY2020 · MH
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$668,094
R01 · FY2020 · MH
Identification of REV-ERB inverse agonists for cancer immunotherapy$643,014
R01 · FY2020 · CA
Optimizing the immune response by targeting the Sts enzymes$572,094
R01 · FY2020 · AI
CHEMOPROTEOMIC METHODS FOR SERINE HYDROLASE INHIBITOR DEVELOPMENT$486,911
R01 · FY2020 · DA
Identification of Chemical Probes for the Orphan Nuclear Receptor NR2F6$469,049
R01 · FY2020 · CA
Development of neutral ceramidase inhibitor tool compounds$390,301
R01 · FY2020 · CA
Parallel Multimodal High-throughput screening to identify activators of the orexin receptors$82,540
R01 · FY2020 · MH
Identification of Chemical Probes for the Orphan Nuclear Receptor NR2F6$54,072
R01 · FY2020 · CA
Parallel Multimodal High-throughput screening to identify activators of the orexin receptors$743,268
R01 · FY2019 · MH
A Scalable Neuron-Based High-Throughput Screening Platform for the Discovery of Compounds that Restore Protein Expression Caused by Genetic Haploinsufficiency$686,767
R01 · FY2019 · MH
Optimizing the immune response by targeting the Sts enzymes$630,428
R01 · FY2019 · AI
Identification of REV-ERB inverse agonists for cancer immunotherapy$547,678
R01 · FY2019 · CA
Identification of Chemical Probes for the Orphan Nuclear Receptor NR2F6$529,984
R01 · FY2019 · CA
Countering beta-lactam resistance in Pseudomonas aeruginosa$513,000
R33 · FY2019 · AI
CHEMOPROTEOMIC METHODS FOR SERINE HYDROLASE INHIBITOR DEVELOPMENT$486,911
R01 · FY2019 · DA
Limiting undesirable effects of opioids by targeting neuronal RGS complexes$480,000
R01 · FY2019 · DA
Development of neutral ceramidase inhibitor tool compounds$458,558
R01 · FY2019 · CA
HTS Drug Discovery Dispensers$452,106
S10 · FY2019 · OD · contact PI
Integrated Acoustic Transfer System for HTS Library Management$623,741
S10 · FY2018 · OD · contact PI
Parallel Multimodal High-throughput screening to identify activators of the orexin receptors$598,887
R01 · FY2018 · MH
Identification of Chemical Probes for the Orphan Nuclear Receptor NR2F6$577,866
R01 · FY2018 · CA
A Scalable Neuron-Based High-Throughput Screening Platform for the Discovery of Compounds that Restore Protein Expression Caused by Genetic Haploinsufficiency$555,274
R01 · FY2018 · MH
Identification of Small Molecules that Influence Trafficking of the GnRH Receptor$538,346
R01 · FY2018 · DK
CHEMOPROTEOMIC METHODS FOR SERINE HYDROLASE INHIBITOR DEVELOPMENT$536,462
R01 · FY2018 · DA
Countering beta-lactam resistance in Pseudomonas aeruginosa$513,000
R33 · FY2018 · AI
Limiting undesirable effects of opioids by targeting neuronal RGS complexes$480,000
R01 · FY2018 · DA
Development of neutral ceramidase inhibitor tool compounds$409,190
R01 · FY2018 · CA
High-Throughput screening for inhibitors of neuroinflammatory lipid production$340,116
R01 · FY2018 · NS
A Scalable Neuron-Based High-Throughput Screening Platform for the Discovery of Compounds that Restore Protein Expression Caused by Genetic Haploinsufficiency$687,348
R01 · FY2017 · MH
CHEMOPROTEOMIC METHODS FOR SERINE HYDROLASE INHIBITOR DEVELOPMENT$610,184
R01 · FY2017 · DA
Countering beta-lactam resistance in Pseudomonas aeruginosa$513,000
R33 · FY2017 · AI
Identification of Small Molecules that Influence Trafficking of the GnRH Receptor$486,319
R01 · FY2017 · DK
Limiting undesirable effects of opioids by targeting neuronal RGS complexes$480,000
R01 · FY2017 · DA
High-Throughput screening for inhibitors of neuroinflammatory lipid production$382,717
R01 · FY2017 · NS
Identification and development of inhibitors of the Hippo-Yap pathway$351,360
R01 · FY2017 · CA
HTS for selective inhibitors of Meprin alpha and beta$322,522
R01 · FY2017 · AR
"A Flexible and Scalable HTS Platform for CNS Probe Discovery"$744,559
R33 · FY2016 · NS
HTS for Direct Targeting of the Transcription Factor MITF$534,190
R01 · FY2016 · CA
Identification of Small Molecules that Influence Trafficking of the GnRH Receptor$514,347
R01 · FY2016 · DK
High-throughput screening for NAD+-replenishing neuroprotective compounds$493,891
R01 · FY2016 · NS
High-Throughput screening for inhibitors of neuroinflammatory lipid production$493,260
R01 · FY2016 · NS
Identification and development of inhibitors of the Hippo-Yap pathway$439,200
R01 · FY2016 · CA
HTS for selective inhibitors of Meprin alpha and beta$364,505
R01 · FY2016 · AR
Countering beta-lactam resistance in Pseudomonas aeruginosa$231,651
R21 · FY2016 · AI
High Throughput Screening for Pharmacoperones of the V2 Receptor$623,890
R01 · FY2015 · DK
HTS for Direct Targeting of the Transcription Factor MITF$587,892
R01 · FY2015 · CA
"A Flexible and Scalable HTS Platform for CNS Probe Discovery"$548,477
R33 · FY2015 · NS
Developing Ubiquitin Ligase Agonists as Cancer Therapeutics$507,502
R01 · FY2015 · CA
High-throughput screening for NAD+-replenishing neuroprotective compounds$490,988
R01 · FY2015 · NS
Identification and development of inhibitors of the Hippo-Yap pathway$439,200
R01 · FY2015 · CA
High Throughput Screening to Discover Chemical Probes of ASK1$381,228
R01 · FY2015 · GM
Countering beta-lactam resistance in Pseudomonas aeruginosa$264,747
R21 · FY2015 · AI
HTS for selective inhibitors of Meprin alpha and beta$174,915
R01 · FY2015 · AR
HTS for selective inhibitors of Meprin alpha and beta$146,126
R01 · FY2015 · AR
High Throughput Screening for Pharmacoperones of the V2 Receptor$537,413
R01 · FY2014 · DK
High-throughput screening for NAD+-replenishing neuroprotective compounds$484,603
R01 · FY2014 · NS
HTS for Direct Targeting of the Transcription Factor MITF$482,741
R01 · FY2014 · CA
Developing Ubiquitin Ligase Agonists as Cancer Therapeutics$460,606
R01 · FY2014 · CA
High Throughput Screening to Discover Chemical Probes of ASK1$381,842
R01 · FY2014 · GM
"A Flexible and Scalable HTS Platform for CNS Probe Discovery"$265,109
R21 · FY2014 · NS
Developing Ubiquitin Ligase Agonists as Cancer Therapeutics$462,467
R01 · FY2013 · CA
High Throughput Screening for Pharmacoperones of the V2 Receptor$450,213
R01 · FY2013 · DK
High Throughput Screening to Discover Chemical Probes of ASK1$436,923
R01 · FY2013 · GM
A muSI-RIAC instrument for multi-bioanalyte assays$99,999
R43 · FY2003 · RR